Results showed that vorapaxar, when added to the standard of care, led to a significant reduction in the risk of the composite of cardiovascular (:CV) death, heart attack, stroke or urgent coronary ...

CHICAGO, IL—In patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) who undergo noncardiac surgery, the novel antiplatelet agent vorapaxar is as safe as placebo through 30 days, ...

Disappointing results were recently presented on Merck’s (NYSE:MRK - News) anti-clotting candidate, vorapaxar, at the American Heart Association. Results from the TRACER (Thrombin Receptor Antagonist ...

The novel antiplatelet agent vorapaxar reduces the total occurrence of myocardial infarction (MI) in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), according to a ...

June 20, 2012 (Dallas, Texas) — New data from the peripheral arterial disease (PAD) subgroup of the TRA 2°P TIMI 50 trial have suggested that the protease-activated receptor 1 (PAR-1) antagonist ...

The novel antiplatelet vorapaxar, which blocks the thrombin receptor to inhibit platelet activation, ran into trouble in the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute ...

A few years ago a novel antiplatelet agent from Merck seemed all but dead. Vorapaxar, a thrombin receptor antagonist, was widely thought to have no future after unacceptably high serious bleeding ...

In a prespecified subanalysis, 16,896 patients with a history of MI (but with no history of stroke or transient ischaemic attack, which are contraindications for vorapaxar) were identified. Of these ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease, the use of vorapaxar appears to reduce peripheral ...

February 7, 2012 (Whitehouse Station, New Jersey) — Merck has announced top-line results of the TRA 2⁰P TIMI-50 study of its novel protease-activated receptor 1 (PAR-1) antagonist antiplatelet agent ...

The primary goals of antiplatelet therapy in peripheral artery disease are the prevention of cardiovascular ischaemic events and maintenance of revascularization patency. Vorapaxar is a novel agent ...